Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Polyclonal EZH2 Primary Antibody for ChIPSeq, ChIP - ABIN2668958
Knutson, Kawano, Minoshima, Warholic, Huang, Xiao, Kadowaki, Uesugi, Kuznetsov, Kumar, Wigle, Klaus, Allain, Raimondi, Waters, Smith, Porter-Scott, Chesworth, Moyer, Copeland, Richon, Uenaka, Pollock et al.: Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. ... in Molecular cancer therapeutics 2014
Show all 9 Pubmed References
Human Monoclonal EZH2 Primary Antibody for ChIP - ABIN2668955
Bengani, Mendiratta, Maini, Vasanthi, Sultana, Ghasemi, Ahluwalia, Ramachandran, Mishra, Brahmachari: Identification and Validation of a Putative Polycomb Responsive Element in the Human Genome. in PLoS ONE 2013
Show all 8 Pubmed References
Human Polyclonal EZH2 Primary Antibody for WB - ABIN2668957
Izzo, Mercogliano, Venturutti, Tkach, Inurrigarro, Schillaci, Cerchietti, Elizalde, Proietti: Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. in Breast cancer research : BCR 2015
Show all 7 Pubmed References
Polyclonal EZH2 Primary Antibody for WB - ABIN540724
Hobert, Jallal, Ullrich: Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. in Molecular and cellular biology 1996
Show all 3 Pubmed References
Human Polyclonal EZH2 Primary Antibody for WB - ABIN2668964
Kaneko, Li, Son, Xu, Margueron, Neubert, Reinberg: Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. in Genes & development 2010
Show all 2 Pubmed References
Human Polyclonal EZH2 Primary Antibody for ICC, IF - ABIN438771
Hyland, McDade, McCloskey, Dickson, Arthur, McCance, Patel: Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. in Journal of virology 2011
Human Monoclonal EZH2 Primary Antibody for IF, IHC (p) - ABIN659002
Tsai, Manor, Wan, Mosammaparast, Wang, Lan, Shi, Segal, Chang: Long noncoding RNA as modular scaffold of histone modification complexes. in Science (New York, N.Y.) 2010
Show all 6 Pubmed References
Study shows that the PRC2 core components are enriched in retinal progenitors and downregulated in differentiated cells. Knockdown of the PRC2 core component Ezh2 leads to reduced retinal progenitor proliferation.
Preferential binding of G-quadruplex RNA is conserved, surprisingly using different protein elements. Key RNA-binding residues are spread out along the surface of EZH2.
in vitro restoration of PAR5 (show YWHAZ Antibodies) expression inhibited human glioma cell proliferation, invasion and migration by binding to EZH2 and regulating oncogene (show RAB1A Antibodies) expression. This finding may provide a therapeutic approach for the future treatment of glioma
Results identified EZH2 as a direct downstream target gene of miR (show MLXIP Antibodies)-137 in cervical cancer (CC). Forced overexpression of EZH2 in miR (show MLXIP Antibodies)-137-upregulated CC cells reversed the tumor-suppression induced by miR (show MLXIP Antibodies)-137.
DANCR associated with EZH2 and HDAC3 (show HDAC3 Antibodies) to epigenetically silence lncRNA-LET and then regulated gastric cancer cells migration and invasion.
the induction of EZH2 led to beta-catenin (show CTNNB1 Antibodies) signaling activation by increasing H3K27me3 on the promoter of SFRP1 (show SFRP1 Antibodies), while the inhibition of EZH2 silenced beta-catenin (show CTNNB1 Antibodies) signaling. Finally, intraarticular injection of EPZ005687 delayed OA development in mice. These results implicated EZH2 activity in OA development. Pharmacological inhibition of EZH2 may be an effective therapeutic approach for osteoarthritis.
The mutation of Y641 and A677 present in the active region of the protein alters the interaction of the top ranked compound with the newly modeled binding groove of the SET domain, giving a GLIDE (show GCM1 Antibodies) score of -12.26 kcal/mol (show DUOXA1 Antibodies), better than that of the wild type at -11.664 kcal/mol (show DUOXA1 Antibodies).
Long noncoding RNA ILF3-AS1 (show PTGDR Antibodies) promotes EZH2-mediated cell proliferation, migration, and invasion via negatively regulating miR (show MLXIP Antibodies)-200b/a/429 in melanoma.
HOXA11 (show HOXA11 Antibodies)-AS acted as an oncogenic long non-coding RNA that promoted cell growth and metastasis of glioma through regulating miR (show MLXIP Antibodies)-214-3p/EZH2 axis.
PRC2-mediated repression of SMARCA2 (show SMARCA2 Antibodies) predicts EZH2 inhibitor activity in SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) mutant tumors.
Findings indicate a mechanism fot the role of enhancer of zeste homolog 2 (EZH2) in ovarian cancer cisplatin resistance.
EZH2 plays a nonclassical role in the regulation of spermatogonial differentiation and apoptosis in murine spermatogenesis.
macroH2A1.1 (show H2AFY Antibodies) (mH2A1.1), a variant of histone H2A, was upregulated during adipocyte differentiation in 3T3-L1 cells and in the white adipose tissue of obese mice. mH2A1.1 regulated Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathway by cooperating with EZH2, a histone H3K27 methyltransferase, thus led to accumulation of H3K27me2 and H3K27me3 on the promoters of Wnt (show WNT2 Antibodies) genes.
miR (show MLXIP Antibodies)-203 is repressed by EZH2 in both embryonic and adult neural stem/progenitor cells (NSPCs). MiR (show MLXIP Antibodies)-203 negatively regulates the proliferation of NSPCs. One of PRC1 (show PRC1 Antibodies) components, Bmi1 (show BMI1 Antibodies), is a downstream target of miR (show MLXIP Antibodies)-203 in NSPCs.
findings highlight an epigenetic mechanism by which EZH2 integrates the multifaceted effects of TNFalpha (show TNF Antibodies) signaling to promote the inflammatory response and apoptosis in colitis.
cardiomyocyte-specific loss of Ezh2 did not affect fibrotic scar size after MI or apical resection at P7, suggesting that it does not extend the regenerative time window. Our results demonstrate that Ezh2 is not required for innate neonatal cardiac regeneration
results, together with our previous report, support a cell lineage-specific mechanism of Ezh2-mediated gene repression, especially those critically involved in cellular function and homeostasis
CARM1 (show CARM1 Antibodies) promotes EZH2-mediated silencing of EZH2/BAF155 (show SMARCC1 Antibodies) target tumor suppressor genes by methylating BAF155 (show SMARCC1 Antibodies).
EZH2 mediates germinal centre (GC) formation through epigenetic silencing of CDKN1A (show CDKN1A Antibodies) and release of cell cycle checkpoints.
Ezh2 is essential to sustain tissue integrity and to set up proper maternal mRNA contribution.
ezh2-deficient mutants fail to properly regenerate their spinal cord after caudal (show CAD Antibodies) fin transection suggesting that Ezh2 and H3K27me3 methylation might also be involved in the process of regeneration in zebrafish.
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Multiple alternatively splcied transcript variants encoding distinct isoforms have been identified for this gene.
enhancer of zeste 2
, enhancer of zeste homolog 2 (Drosophila)
, Polycomb protein EZH2
, histone-lysine N-methyltransferase EZH2
, histone-lysine N-methyltransferase EZH2-like
, Enhancer of zeste homolog 2-A
, Polycomb protein EZH2-A
, lysine N-methyltransferase 6
, enhancer of zeste homolog 2
, eyes absent homolog 2